Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors-Reference-Cited by-同舟云学术

Developing a Biased Unmatched Bivalent Ligand (BUmBL) Design Strategy to Target the GPCR Homodimer Allosteric Signaling (cAMP over β-Arrestin 2 Recruitment) Within the Melanocortin Receptors

Published:2018-04-18 Issue:1 Volume:62 Page:144-158
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lensing Cody J.¹,Freeman Katie T.¹,Schnell Sathya M.¹,Speth Robert C.²³,Zarth Adam T.¹⁴,Haskell-Luevano Carrie¹^ORCID

Affiliation:

1. Department of Medicinal Chemistry and Institute for Translational Neuroscience, University of Minnesota, 308 Harvard Street SE, Minneapolis, Minnesota 55455, United States

2. College of Pharmacy, Nova Southeastern University, Fort Lauderdale, Florida 33328-2018, United States

3. Department of Pharmacology and Physiology, Georgetown University, Washington, D.C. 20057, United States

4. Masonic Cancer Center, University of Minnesota, 2231 Sixth Street SE, 2-210 CCRB, Minneapolis, Minnesota 55455, United States

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

College of Pharmacy,?University of Minnesota

University of Minnesota

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b00238

Reference123 articles.

1. Trends in the exploitation of novel drug targets

2. A comprehensive map of molecular drug targets

3. G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives

4. The GPCR heterotetramer: challenging classical pharmacology

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Apelin receptor dimer: Classification, future prospects, and pathophysiological perspectives;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-08

2. Incorporation of Three Extracyclic Arginine Residues into a Melanocortin Macrocyclic Agonist (c[Pro-His-DPhe-Arg-Trp-Dap-Lys(Arg-Arg-Arg-Ac)-DPro]) Decreases Food Intake When Administered Intrathecally or Subcutaneously Compared to a Macrocyclic Ligand Lacking Extracyclic Arginine Residues (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro)];ACS Pharmacology & Translational Science;2024-04-02

3. Study of G protein-coupled receptors dimerization: From bivalent ligands to drug-like small molecules;Bioorganic Chemistry;2023-11

4. The Parallel Structure–Activity Relationship Screening of Three Compounds Identifies the Common Agonist Pharmacophore of Pyrrolidine Bis-Cyclic Guanidine Melanocortin-3 Receptor (MC3R) Small-Molecule Ligands;International Journal of Molecular Sciences;2023-06-14

5. Discovery of a Pan-Melanocortin Receptor Antagonist [Ac-DPhe(pI)-Arg-Nal(2′)-Orn-NH₂] at the MC1R, MC3R, MC4R, and MC5R that Mediates an Increased Feeding Response in Mice and a 40-Fold Selective MC1R Antagonist [Ac-DPhe(pI)-DArg-Nal(2′)-Arg-NH₂];Journal of Medicinal Chemistry;2023-06-12